Faruqi & Faruqi, LLP is investigating claims against Medpace Holdings following the company's announcement of a lower-than-expected book-to-bill ratio for Q4 2025. Medpace had previously assured investors of stable cancellation rates and strong growth, but revealed a ratio of 1.04 instead of the projected 1.15, causing the stock to fall over 15.9%. Investors who bought Medpace securities between April 22, 2025, and February 9, 2026, are encouraged to contact the law firm to discuss their legal options before the June 8, 2026 deadline to seek lead plaintiff status in the class action lawsuit. The case centers on allegations that Medpace misled investors by hiding adverse facts about its backlog cancellations and growth prospects.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
